|Day's Range||20.32 - 22.50|
|52 Week Range||13.60 - 33.00|
|PE Ratio (TTM)||-19.23|
|Earnings Date||Jul 27, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||27.13|
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Acorda Therapeutics, Inc. Here are 5 ETFs with the largest exposure to ACOR-US. Comparing the performance and risk of Acorda Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Acorda Therapeutics, Inc. will host a conference call and webcast to review its second quarter 2017 financial results and pipeline updates on Thursday, July 27 at 8:30 a.m.
Acorda Therapeutics, Inc. (ACOR) has submitted a new drug application to FDA for its late stage pipeline candidate Inbrija for treatment of patients suffering from Parkinson's disease.